Is cytarabine required in the treatment of acute promyelocytic leukemia? Updated experience and review of the literature

Clinical Advances in Hematology and Oncology

Volumn 4, Issue 9, 2006, Pages 678-682

  Adès, Lionel ^a   Fenaux, Pierre ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

Acute promyelocytic leukemia; ATRA; Cytarabine; Randomized trial

Indexed keywords

AMSACRINE; ANTHRACYCLINE DERIVATIVE; ARSENIC DERIVATIVE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; RETINOIC ACID;

BLAST CELL; BONE MARROW SUPPRESSION; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; HIGH RISK PATIENT; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LEUKOCYTOSIS; PROMYELOCYTIC LEUKEMIA; RETINOIC ACID SYNDROME; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 33749873667     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451-458.
2. Larson RA, Kondo K, Vardiman JW, Butler AE, Golomb HM, Rowley JD. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med. 1984;76:827-841.
3. De The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 1991;66:675-684.
4. Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood. 1992;79:543-553.
5. Cunningham I, Gee TS, Reich LM, Kempin SJ, Naval AN, Clarkson BD. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood. 1989;73:1116-1122.
6. Fenaux P, Pollet JP, Vandenbossche L, Dupriez B, Jouet JP, Bauters F. Treatment of acute promyelocytic leukemia: a report on 70 cases. Leuk Lymphoma. 1991;4:249.
7. Head DR, Kopecky KJ, Willman C, Appelbaum FR. Treatment outcome with chemotherapy in acute promyelocytic leukemia: the Southwest Oncology Group (SWOG) experience. Leukemia. 1994;8:S38-S41.
8. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567-572.
9. Warrell RP Jr, Frankel SR, Miller WH Jr, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991;324:1385-1393.
10. Fenaux P, Castaigne S, Chomienne C, Dombret H, Degos L. All trans retinoic acid treatment for patients with acute promyelocytic leukaemia. Leukemia. 1992;6:64.
11. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr. The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med. 1992;117:292-296.
12. De Botton S, Dombret H, Sanz M, et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1998;92:2712-2718.
13. Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood. 1993;82:3241-3249.
14. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021-1028.
15. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic, acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999;94:1192-1200.
16. Ades L, Chevret S, De Botton S, et al; European APL Group. Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia. 2005;19:230-233.
17. Marty M, Ganem G, Fischer J, et al. Acute promyelocytic leukemia: retrospective study of 119 patients treated with daunorubicin. Nouv Rev Fr Hematol. 1984;26:371-378.
18. Avvisati G, Perri MC, Lo-Coco F, et al; GIMEMA (Gruppo Italiano Malattie Ematologische dell'Adulto) Italian Cooperative Group. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood. 2002;100:3141-3146.
19. Head D, Kopecky KJ, Weick J, et al. Effect of aggressive daunomycin therapy on survival in acute promyelocyti leukemia. Blood. 1995;86:1717-1728.
20. Estey E, Thall PF, Pierce S, Kantarjian H, Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol. 1997;15:483-490.
21. Sanz MA, Martin G, Gonzalez M, et al; Programa de Estudio y Traitmiento de las Hemopatias Malignas. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103:1237-1243.
22. Ades L, Raffoux E, Chevret S, et al. Is araC required in the treatment of newly diagnosed APL? Results of a randomized trial (APL 2000) [abstract]. Blood. 2004;104(11 pt 1):115a. Abstract 391.
23. Masaoka T, Ogawa M, Yamada K, Kimura K, Ohashi Y. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia. Semin Hematol. 1996;33(4 suppl 3):12-17.
24. Berman E, Wiernik P, Vogler R, Velez-Garcia E, Bartolucci A, Whaley FS. Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia. Cancer. 1997;80(11 suppl):2181-2185.
25. Lo Coco F, G Avvisati, M Vignetti, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation: results of the AIDA-2000 trial of the Italian GIMEMA group [abstract]. Blood. 2004;104(11 pt 1):115a. Abstract 392.
26. Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative group. Blood. 2000;96:1247-1253.
27. Kanamaru A, Takemoto Y, Tanimoto M, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood. 1995;85:1202-1206.
28. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood. 1999;93:4131-4143.
29. Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood. 1999;94:3015-3021.
30. Lengfelder E, Reichert A, Schoch C, et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia. 2000;14:1362-1370.